High precision innovative micropump for artificial pancreas

The concept of artificial pancreas, which comprises an insulin pump, a continuous glucose meter and a control algorithm, is a major step forward in managing patient with type 1 diabetes mellitus. The stability of the control algorithm is based on short-term precision micropump to deliver rapid-acting insulin and to specific integrated sensors able to monitor any failure leading to a loss of accuracy. Debiotech’s MEMS micropump, based on the membrane pump principle, is made of a stack of 3 silicon wafers. The pumping chamber comprises a pillar check-valve at the inlet, a pumping membrane which is actuated against stop limiters by a piezo cantilever, an anti-free-flow outlet valve and a pressure sensor. The micropump inlet is tightly connected to the insulin reservoir while the outlet is in direct communication with the patient skin via a cannula. To meet the requirement of a pump dedicated to closed-loop application for diabetes care, in addition to the well-controlled displacement of the pumping membrane, the high precision of the micropump is based on specific actuation profiles that balance effect of pump elasticity in low-consumption push-pull mode.

[1]  W. Tamborlane,et al.  Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. , 1979, The New England journal of medicine.

[2]  W. Tamborlane,et al.  A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. , 2004, Diabetes care.

[3]  Juan G. Santiago,et al.  A review of micropumps , 2004 .

[4]  B. Bequette A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. , 2005, Diabetes technology & therapeutics.

[5]  Henry Anhalt,et al.  Insulin patch pumps: their development and future in closed-loop systems. , 2010, Diabetes technology & therapeutics.

[6]  A. Berghold,et al.  Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis , 2008, Diabetologia.

[7]  C. Cobelli,et al.  Artificial Pancreas: Past, Present, Future , 2011, Diabetes.

[8]  I. Hirsch,et al.  Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. , 2005, Diabetes care.

[9]  F. Bianchi,et al.  Industrialized Functional Test for Insulin Micropumps , 2011 .

[10]  B. Wayne Bequette,et al.  Challenges and recent progress in the development of a closed-loop artificial pancreas , 2012, Annu. Rev. Control..